Increasing cases of dysphagia to propel the 3d printed drugs market growth
According to a new report published by Reports Monitor titled, “Global 3D Printed Drugs, Growth Opportunities, Innovations and Forecast, 2018-2025,” the 3D printed drugs market was valued at XX million in 2018 and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2018 to 2025.
These drugs are being manufactured for the old, elderly populations or individuals suffering from diseases and conditions such as dysphagia. These conditions can be the result of surgery, or 30 diverse health events including neurological conditions, digestive disorders, head injuries or even developmental disability in children. Hence it can be said that a large population worldwide suffer from swallowing problem and 3D printed drugs provide better opportunity and solutions for such patients.Manufacturers are targeting highly prescribed drugs and most common diseases to increase personalization so that patients can treat themselves and will be able to customize doses, which will reduce hospitals visits and stays and overall cost for the patients.
This report provides a detailed analysis of 3D printed drugs, which includes current industry situations such as market size, growth and demands, market outlook, major players with their key strategies.It covers the market canvas and the growth opportunities in the coming years. The report has been made with an in-depth analysis along with important inputs from the various industry experts. The research is carried out with both extensive primary and secondary data sources supported with either bottom up or top down approach.
Pharmaceutical giant such as GlaxoSmithKline is also running early stage program for determining the feasibility of highly prescribed 3D printed pills. Many start-ups such as FabRX and others are also working on using 3D printing technology for drug and medicine manufacturing, providing a platform to formulate and manufacture 3D printed medications with any drug compound.Multiply Labs have used the 3D printing technology to manufacture supplement capsules. This customizable capsule allows the user to take single supplement capsules instead of so many pills. Focusing on the customer demand and increasing health concern the demand for such customizable drugs may increase rapidly in the near future.
The global 3D printed drugs market is majorly studied across: North America, Europe, Asia Pacific and LAMEA (Latin America, Middle East and Africa).U.S. Holds the maximum market share of the 3D printed drug with Spritamadapted by most of the population suffering from major disorders.
The major key players operating in the market are: Aprecia Pharmaceuticals, FabRX, MultiPly Labs, GlaxoSmithKline, and Astrazeneca.
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.